| Followers | 200 |
| Posts | 25596 |
| Boards Moderated | 0 |
| Alias Born | 04/03/2010 |
Saturday, September 25, 2021 9:25:06 PM
That info is for parties who have invested in that venture, which is a CDMO. Honestly, you should enquirer if you can invest in 1) Toucan; or 2) Advent directly.
But an investment in a CDMO is not an investment in a drug company. It is a very particular business and I would bet it is primarily for those who understand that it is not the core business but is a way to make a living, not to get wealthy, generally, though certainly if you own the most of it, a large shareholder could do well in almost any business, even a low margin, capital intensive business. Personally, such a business would not be for me. If I were a scientist looking for a way to turn know know how and skills into ready cash flow, it would be very interesting. But from my perspective as a contributor of capital, it is not so interesting.
But an investment in a CDMO is not an investment in a drug company. It is a very particular business and I would bet it is primarily for those who understand that it is not the core business but is a way to make a living, not to get wealthy, generally, though certainly if you own the most of it, a large shareholder could do well in almost any business, even a low margin, capital intensive business. Personally, such a business would not be for me. If I were a scientist looking for a way to turn know know how and skills into ready cash flow, it would be very interesting. But from my perspective as a contributor of capital, it is not so interesting.
Recent NWBO News
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
